PIPELINE

Pipeline

Pipeline table
Pipeline Target Indication Discovery Pre-clinical Phase 1 Phase 2 Phase 3
MFC0101
(BBB-permeable, undruggable IDP target)
Glioblastoma
37%
Solid Tumors
30%
Brain Metastases
20%
MFC0102
(Non-BBB-permeable, undruggable IDP target)
MASH
15%
Solid Tumors
15%
MFC0201
(undruggable IDP target)
Solid Tumors
9%
MFC0301
(undruggable IDP target)
Solid Tumors
13%